Maravai LifeSciences Holdings, Inc. (MRVI)
NASDAQ: MRVI · Real-Time Price · USD
3.700
0.00 (0.00%)
At close: Dec 5, 2025, 4:00 PM EST
3.606
-0.095 (-2.55%)
After-hours: Dec 5, 2025, 5:58 PM EST
| Period Ending | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Nucleic Acid Production | 151.68M | 179.08M | 196.35M | 213.27M | 214.55M | 209.33M | 224.77M | 355.23M | |||||||||||
| Nucleic Acid Production Growth | -29.30% | -14.45% | -12.65% | -39.96% | -55.20% | -67.84% | -72.36% | -57.52% | |||||||||||
| Biologics Safety Testing | 64.32M | 62.93M | 62.99M | 63.65M | 64.03M | 64.77M | 64.18M | 64.29M | |||||||||||
| Biologics Safety Testing Growth | 0.45% | -2.84% | -1.85% | -0.99% | -1.53% | -3.13% | -8.23% | -8.74% | |||||||||||
| Protein Detection | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 25.44M | 26.24M | 23.31M | 22.88M |
Adjusted EBITDA by Segment
| Period Ending | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Biologics Safety Testing | 44.00M | 42.59M | 43.84M | 45.90M | 46.22M | 47.09M | 46.91M | 46.52M | |||||||||||
| Biologics Safety Testing Growth | -4.80% | -9.56% | -6.54% | -1.33% | -4.25% | -9.54% | -14.47% | -16.77% | |||||||||||
| Nucleic Acid Production | 3.25M | 31.83M | 50.81M | 70.85M | 71.98M | 64.87M | 82.66M | 194.09M | |||||||||||
| Nucleic Acid Production Growth | -95.48% | -50.94% | -38.53% | -63.50% | -76.88% | -86.58% | -87.05% | -70.88% |
Revenue by Geography
| Period Ending | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| North America | 121.31M | 122.99M | 127.09M | 132.08M | 131.91M | 133.92M | 141.06M | 174.99M | |||||||||||
| North America Growth | -8.03% | -8.16% | -9.90% | -24.52% | -44.62% | -54.30% | -58.45% | -50.34% | |||||||||||
| APAC | 63.54M | 78.80M | 89.38M | 93.60M | 95.30M | 89.21M | 97.44M | 113.10M | |||||||||||
| APAC Growth | -33.33% | -11.67% | -8.27% | -17.24% | -4.65% | -24.38% | -11.25% | 19.34% | |||||||||||
| EMEA | 30.42M | 39.57M | 42.06M | 50.53M | 50.69M | 50.30M | 49.92M | 130.78M | |||||||||||
| EMEA Growth | -40.00% | -21.33% | -15.76% | -61.36% | -75.27% | -83.56% | -88.47% | -71.50% | |||||||||||
| Latin and Central America | 586.00K | 501.00K | 662.00K | 706.00K | 686.00K | 681.00K | 527.00K | 649.00K | |||||||||||
| Latin and Central America Growth | -14.58% | -26.43% | 25.62% | 8.78% | -14.04% | -19.60% | -34.78% | -5.67% |
Source: Business metrics provided by Main Street Data and sourced from official company press releases and documents.